Showing results (101-110 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|August 8, 2022
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 studyReinhard Dummer, Paola Queirolo, Ana Maria Abajo Guijarro, et al.
The Lancet. Oncology|September 16, 2021
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgeryJoe Y Chang, Reza J Mehran, Lei Feng, et al.
The Lancet. Oncology|September 3, 2021
Radiotherapy resources in Africa: an International Atomic Energy Agency update and analysis of projected needsShekinah N C Elmore, Alfredo Polo, Jean-Marc Bourque, et al.
The Lancet. Oncology|September 3, 2021
The UK's contribution to cancer control in low-income and middle-income countriesSusannah Stanway, Mark Lodge, Richard Sullivan, et al.
The Lancet. Oncology|August 30, 2025
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trialAndrea Necchi, Félix Guerrero-Ramos, Paul L Crispen, et al.
The Lancet. Oncology|May 19, 2015
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trialsJoe Y Chang, Suresh Senan, Marinus A Paul, et al.
The Lancet. Oncology|May 19, 2015
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset-Seguin, Axel Hauschild, Jean-Jacques Grob, et al.
The Lancet. Oncology|May 19, 2015
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 studyGottfried E Konecny, Neil Finkler, Agustin A Garcia, et al.
The Lancet. Oncology|May 1, 2020
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trialSara M Tolaney, Andrew M Wardley, Stefania Zambelli, et al.
The Lancet. Oncology|August 7, 2021
Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysisJacob G Scott, Geoffrey Sedor, Patrick Ellsworth, et al.
Pageof 336